Giant cell myocarditis. Issue 3 (4th May 2021)

• Record Type: Journal Article
• Authors: Gadela, Naga Vaishnavi; Krishnan, Anand Muthu; Mukarram, Osama; Sthalekar, Nitya
• Is Part Of: Proceedings. Volume 34:Issue 3(2021)
• Page Start: 401
• Page End: 402
• Publication Date: 2021-05-04
• Subjects: Cardiomyopathy -- giant cell myocarditis -- heart transplantation -- immunosuppressive regimen -- ventricular arrhythmias; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2021.1874775
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Giant cell myocarditis (GCM) usually affects previously healthy adults and is a rapidly progressive and frequently fatal disease. It has a median survival of 3 months to death or transplant without appropriate therapy. Hence, early diagnosis is critical, with evidence showing rapidly instituted cyclosporine-based immunosuppression can improve transplant-free survival. Although transplant is an effective strategy, GCM can recur in 25% of transplanted hearts. We present a case of GCM in a patient who presented with conduction abnormalities and fulminant heart failure.